Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration  - HEAVEN Study -

Kovárník, Tomáš; Mintz, Gary S.; Skalická, Hana; Král, Aleš; Horák, Jan; Škulec, Roman; Uhrová, Jana; Martásek, Pavel; Downe, Richard; Wahle, Andreas; Sonka, Milan; Mrázek, Vratislav; Aschermann, Michael; Linhart, Aleš

doi:10.1253/circj.cj-11-0730

Cited by 75 publications

(55 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Kovarnik et al also reported the same results using dual lipid-lowering therapy with statin plus ezetimibe. 23 In the present study, the FF plaque component decreased under statin therapy in both DM and non-DM patients, which illustrated the potential effects of statin against coronary events even in DM patients. The FF component under statin therapy, however, was significantly greater in DM pa- Plaque progression occurs primarily because of an increase in the FI component.…”

Section: Discussionsupporting

confidence: 72%

Impact of Diabetes Mellitus on Coronary Atherosclerosis and Plaque Composition Under Statin Therapy

Nozue

Yamamoto

Tohyama

et al. 2012

Circ J

View full text Add to dashboard Cite

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp iabetes mellitus (DM) is a risk factor for the development of coronary artery disease (CAD), 1 and DM patients have a markedly increased incidence of adverse cardiovascular events. 2 The mechanisms underlying this increased incidence, however, have not been well-characterized.Recent clinical trials using gray-scale intravascular ultrasound (IVUS) have shown that intensive lipid-lowering therapy with statins resulted in regression of coronary artery plaques 3 and reduced the risk of coronary events.

show abstract

Section: Discussionsupporting

confidence: 72%

Impact of Diabetes Mellitus on Coronary Atherosclerosis and Plaque Composition Under Statin Therapy

Nozue

Yamamoto

Tohyama

et al. 2012

Circ J

View full text Add to dashboard Cite

show abstract

“…24 On closer Varying Statin Doses on VH-IVUS Composition examination of the individual VH-IVUS components in our study (Figure 3), the fibrous component was significantly reduced by statin treatment in either group but showed no statistically significant difference between the 2 groups. The changes in fibro-fatty component were too elusive to allow for any conclusion to be drawn from this small sample.…”

Section: Potential Inaccuracy Of Vh-ivus As Compared To Ib-ivusmentioning

confidence: 54%

“…23 In another very recently published report (the Heaven Study by Kovarnik et al), a 12-month dual lipid-lowering therapy (atorvastatin 80 mg and ezetimibe 10 mg) was compared to atorvastatin 10 mg alone. 24 Plaque regression was achieved in the dual therapy group only, yet in both groups treated with atorvastatin, a continuous shift (reduction) of fibrous and fibrofatty component towards (increase) dense calcium and necrotic core was observed. Comparing this recent report with our present study, which also used atorvastatin, both studies showed almost identical trends of plaque composition changes (a closely matched observation of continuous shift in plaque compositions from fibrous and fibro-fatty tissue to dense calcium and necrotic core).…”

Section: Possible Statin-specific Effects On Plaque Compositionsmentioning

confidence: 85%

Virtual Histology Findings and Effects of Varying Doses of Atorvastatin on Coronary Plaque Volume and Composition in Statin-Naive Patients

Lee

Hau

Kong

et al. 2012

Circ J

View full text Add to dashboard Cite

“…This change in the fibrofatty volume had a significant correlation with changes in the low-density lipoprotein-cholesterol (LDL-C) level (r=0.703, P<0.0001) and in the high-sensitivity C-reactive protein level (r=0.357, P=0.006). 26, 27 Of note, the necrotic core did not change significantly. The same data were found with the use of pitavastatin.…”

Section: Assessment Of Drug Effect On Atherosclerosis By Vh-ivusmentioning

confidence: 93%

Assessment of Plaque Composition by Intravascular Ultrasound and Near-Infrared Spectroscopy

Brugaletta

Sabaté

2014

Circ J

View full text Add to dashboard Cite

Atherosclerosis is the main cause of coronary artery disease (CAD), which is today the leading cause of death worldwide and will continue to be the first in the world in 2030. Vulnerable coronary plaques are usually characterized by a high content of necrotic core, a thin inflamed fibrous cap (intense accumulation of macrophages) and scarce presence of smooth muscle cells. None of these characteristics can be estimated by coronary angiography, which on the contrary underestimates the magnitude of atherosclerotic burden, particularly in earlier stage disease when positive vascular remodeling may allow "normal" lumen caliber despite substantial vascular wall plaque. The recognition of the ubiquity of substantial but non-flow limiting lesions that may be at high risk for subsequent plaque rupture has resulted in a paradigm shift in thinking about the pathophysiology of CAD, with the focus no longer solely on the degree of arterial luminal narrowing. This growing need for more information about coronary atherosclerosis in order to identify patients and lesions at risk for complications during PCI and for future adverse cardiac events has been the primary impetus for the development of novel intracoronary imaging methods able to detect plaque composition, in particular presence of a necrotic core/lipid pool, such as intravascular ultrasound virtual histology and near-infrared spectroscopy. These imaging technologies and their clinical and clinical/research applications are discussed in detail. (Circ J 2014; 78: 1531 -1539

show abstract

Virtual Histology Evaluation of Atherosclerosis Regression During Atorvastatin and Ezetimibe Administration - HEAVEN Study -

Cited by 75 publications

References 34 publications

Impact of Diabetes Mellitus on Coronary Atherosclerosis and Plaque Composition Under Statin Therapy

Impact of Diabetes Mellitus on Coronary Atherosclerosis and Plaque Composition Under Statin Therapy

Virtual Histology Findings and Effects of Varying Doses of Atorvastatin on Coronary Plaque Volume and Composition in Statin-Naive Patients

Assessment of Plaque Composition by Intravascular Ultrasound and Near-Infrared Spectroscopy

Contact Info

Product

Resources

About